The tendency for haemorrhagic stroke in patients with chronic HCV infection has emerged recently but the finding may be confounded by comorbidities. Proving the causality between HCV infection and haemorrhagic stroke is mandatory. Our study was designed to investigate the incidence of intracranial haemorrhage in HCV-infected patients with and without treatment.
Methods
In the 11-year and population-based retrospective study, we acquired data from the Taiwan National Health Insurance Research Database. The patients with major comorbidities were excluded and 97,198 HCV-infected patients were included for analysis. Treated and untreated cohorts were matched with propensity score to make the confounding factors in two groups comparable. Cox proportional hazard regression analysis was performed to evaluate the hazard ratio of haemorrhagic stroke in the cohorts. We applied survival analysis to compare the cumulative incidence of outcome events between the two cohorts.
Results
After matching, the incidence density (ID) of haemorrhagic stroke in the untreated cohort is significantly higher than in the treated cohort (ID: 1.0 versus 0.6 events per 1,000 person-years; P=0.0014). The adjusted hazard ratio (aHR) of haemorrhagic stroke is significantly reduced in the treated group (P<0.05). Cumulative incidence of haemorrhagic stroke is significantly lower in the treated group than in the untreated group (P=0.013).
Conclusions
The study demonstrates that antiviral therapy significantly reduces the events of intracranial haemorrhage in HCV-infected patients and consolidates the novel concept that chronic HCV infection is a risk factor for haemorrhagic stroke.
References
1.
MessinaJ.P., HumphreysI., FlaxmanA.Global distribution and prevalence of hepatitis C virus genotypes.Hepatology2015; 61: 77–87.
2.
ArzumanyanA., ReisH.M., FeitelsonM.A.Pathogenic mechanisms in HBV- and HCV-associated hepatocellular carcinoma.Nat Rev Cancer2013; 13: 123–135.
3.
YounossiZ.M., StepanovaM., NaderF.Associations of chronic hepatitis C with metabolic and cardiac outcomes.Aliment Pharmacol Ther2013; 37: 647–652.
4.
AraseY., SuzukiF., SuzukiY.Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C.Hepatology2009; 49: 739–744.
5.
OlubamwoO.O., AregbesolaA.O., MiettolaJ.Hepatitis C and risk of coronary atherosclerosis - a systematic review.Public Health2016; 138: 12–25.
6.
LinM.S., GuoS.E., ChenM.Y.The impact of hepatitis C infection on ischemic heart disease via ischemic electrocardiogram.Am J Med Sci2014; 347: 478–484.
7.
PipiliC., IlonidisG., CholongitasE.Hepatitis C virus and kidney: a strong association with different clinical aspects.Liver Int2011; 31: 1071–1080.
8.
LeeM.H., YangH.I., WangC.H.Hepatitis C virus infection and increased risk of cerebrovascular disease.Stroke2010; 41: 2894–2900.
9.
CacoubP., SaadounD., LimalN.Hepatitis C virus infection and mixed cryoglobulinaemia vasculitis: a review of neurological complications.AIDS2005; 19Suppl 2: S128–S134.
10.
HsuY.C., HoH.J., HuangY.T.Association between antiviral treatment and extrahepatic outcomes in patients with hepatitis C virus infection.Gut2015; 64: 495–503.
11.
NegroF., FortonD., CraxiA.Extrahepatic morbidity and mortality of chronic hepatitis C.Gastroenterology2015; 149: 1345–1360.
12.
GillK., GhazinianH., ManchR.Hepatitis C virus as a systemic disease: reaching beyond the liver.Hepatol Int2016; 10: 415–423.
13.
PettaS., MaidaM., MacalusoF.S.Hepatitis C virus infection is associated with increased cardiovascular mortality: a meta-analysis of observational studies.Gastroenterology2016, 150: 145–155.e144.
14.
HsuC.S., KaoJ.H., ChaoY.C.Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.Aliment Pharmacol Ther2013; 38: 415–423.
15.
AdinolfL.E., ZampinoR., RestivoL.Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms.World J Gastroenterol2014; 20: 3410–3417.
16.
TsengC.H., MuoC.H., HsuC.Y.Increased risk of intracerebral hemorrhage among patients with hepatitis C virus infection.Medicine2015; 94: e2132.
17.
KaribeH., NiizumaH., OhyamaH.Hepatitis C virus (HCV) infection as a risk factor for spontaneous intracerebral hemorrhage: hospital based case-control study.J Clin Neurosci2001; 8: 423–425.
18.
AraseY., KobayashiM., KawamuraY.Impact of virus clearance for the development of hemorrhagic stroke in chronic hepatitis C.J Med Virol2014; 86: 169–175.
YuM.L., ChuangW.L.Treatment of chronic hepatitis C in Asia: when East meets West.J Gastroenterol Hepatol2009; 24: 336–345.
21.
OmataM., KandaT., YuM.L.APASL consensus statements and management algorithms for hepatitis C virus infection.Hepatol Int2012; 6: 409–435.
22.
ChangC.H., ShauW.Y., KuoC.W.Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study.Stroke2010; 41: 1884–1890.
23.
RosenbaumP.R., RubinD.B.The central role of the propensity score in observational studies for causal effects.Biometrika1983; 70: 41–55.
24.
BerryS.D., NgoL., SamelsonE.J.Competing risk of death: an important consideration in studies of older adults.J Am Geriatr Soc2010; 58: 783–787.
25.
YuM.L., DaiC.Y., HuangJ.F.A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C.Gut2007; 56: 553–559.
26.
LiuC.H., LiuC.J., LinC.L.Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.Clin Infect Dis2008; 47: 1260–1269.
27.
LuM.C., GuoH.R., LinM.C.Bidirectional associations between rheumatoid arthritis and depression: a nationwide longitudinal study.Sci Rep2016; 6: 20647.
28.
SchaeferM., CapuronL., FriebeA.Hepatitis C infection, antiviral treatment and mental health: a European expert consensus statement.J Hepatol2012; 57: 1379–1390.
29.
O'DonnellM.J., XavierD., LiuL.Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study.Lancet2010; 376: 112–123.
30.
BadenR., RockstrohJ.K., ButiM.Natural history and management of hepatitis C: does sex play a role?J Infect Dis2014; 209Suppl 2: S81–S85.
31.
LipG.Y., LinH.J., HsuH.C.Comparative assessment of the HAS-BLED score with other published bleeding risk scoring schemes, for intracranial haemorrhage risk in a non-atrial fibrillation population: the Chin-Shan Community Cohort Study.Int J Cardiol2013; 168: 1832–1836.
32.
ElgouhariH.M., ZeinC.O., HanounehI.Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection.Dig Dis Sci2009; 54: 2699–2705.
33.
DurandM., SheehyO., BarilJ.G.Risk of spontaneous intracranial hemorrhage in HIV-infected individuals: a population-based cohort study.J Stroke Cerebrovasc Dis2013; 22: e34–e41.
34.
GrønbaekH., JohnsenS.P., JepsenP.Liver cirrhosis, other liver diseases, and risk of hospitalisation for intracerebral haemorrhage: a Danish population-based case-control study.BMC Gastroenterol2008; 8: 16.
35.
TheinH.H., YiQ., DoreG.J.Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression.Hepatology2008; 48: 418–431.
36.
FletcherN.F., WilsonG.K., MurrayJ.Hepatitis C virus infects the endothelial cells of the blood-brain barrier.Gastroenterology2012; 142: 634–643.e6.
37.
Erro AguirreM.E., Ayuso BlancoT., Tunon AlvarezT.Brain hemorrhage as a complication of chronic hepatitis C virus-related vasculitis.J Neurol2008; 255: 944–945.
38.
NúñezO., Fernandez-MartinezA., MajanoP.L.Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins.Gut2004; 53: 1665–1672.
Florczak-RzepkaM., Grond-GinsbachC., MontanerJ.Matrix metalloproteinases in human spontaneous intracerebral hemorrhage: an update.Cerebrovasc Dis2012; 34: 249–262.
